Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

Trial Profile

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs Bortezomib (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms FIL-Veral12
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Mar 2016 Last checked against ClinicalTrials.gov record.
    • 28 Jan 2014 New source identified and integrated (European Clinical Trials Database).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top